Indian Panel Revises Bharat Vaccine Approval Amid 'Objections'

08 Sep 2016
News

Anju Ghangurde @ScripAnjuG anju.ghangurde@informa.com

Executive Summary

Bharat Biotech's quadrivalent (DPT-Hib) vaccine will have to go through Phase III trials after rival Panacea Biotec questions India's market authorization of the product.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

India

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Review Pathway Drug Review Regulation

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS119089

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS119089

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Indian Panel Revises Bharat Vaccine Approval Amid 'Objections'

News

Executive Summary

Related Content

Panacea finds no cure-all for its financial woes

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert